First Time Loading...
J

JCR Pharmaceuticals Co Ltd
TSE:4552

Watchlist Manager
JCR Pharmaceuticals Co Ltd
TSE:4552
Watchlist
Price: 648 JPY -18.8% Market Closed
Updated: May 14, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

102.8B
-1%
Assets
Growth Rates:
1 Year
+12%
3 Years
+55%
5 Years
+160%
7 Years
+183%
10 Years
+222%
47.1B
0%
Liabilities
Growth Rates:
1 Year
+19%
3 Years
+48%
5 Years
+334%
7 Years
+415%
10 Years
+537%
55.7B
-2%
Equity
Growth Rates:
1 Year
+7%
3 Years
+60%
5 Years
+94%
7 Years
+105%
10 Years
+127%

Balance Sheet Decomposition
JCR Pharmaceuticals Co Ltd

102.8B
Assets
47.1B
Liabilities
102.8B
Assets
47.1B
Liabilities
Current Assets 57.5B
Cash & Short-Term Investments 18.3B
Receivables 16.3B
Other Current Assets 22.9B
Non-Current Assets 45.3B
Long-Term Investments 9.3B
PP&E 30.7B
Intangibles 3.6B
Other Non-Current Assets 1.8B
Current Liabilities 31.9B
Accounts Payable 1.6B
Accrued Liabilities 607m
Other Current Liabilities 29.7B
Non-Current Liabilities 15.2B
Long-Term Debt 13.6B
Other Non-Current Liabilities 1.6B

Balance Sheet
JCR Pharmaceuticals Co Ltd

Rotate your device to view
Balance Sheet
Currency: JPY
Mar-2014 Mar-2015 Mar-2016 Mar-2017 Mar-2018 Mar-2019 Mar-2020 Mar-2021 Mar-2022 Mar-2023
Assets
Cash & Cash Equivalents
1 047
1 137
1 949
5 509
4 895
7 836
10 973
26 260
30 733
13 278
Cash Equivalents
1 047
1 137
1 949
5 509
4 895
7 836
10 973
26 260
30 733
13 278
Short-Term Investments
6 197
3 736
1 927
300
1 217
661
220
0
244
0
Total Receivables
3 869
5 204
5 384
5 435
7 103
8 835
7 977
8 183
15 585
11 137
Accounts Receivables
3 869
5 204
5 384
5 435
7 103
8 835
7 977
8 183
15 585
11 137
Other Receivables
0
0
0
0
0
0
0
0
0
0
Inventory
5 105
6 402
7 343
7 738
9 023
9 117
8 855
13 554
14 636
18 514
Other Current Assets
1 154
712
1 763
1 333
593
919
317
548
990
4 873
Total Current Assets
17 373
17 191
18 366
20 315
22 831
27 368
28 342
48 545
62 188
47 802
PP&E Net
11 392
11 612
11 445
11 388
10 853
11 061
14 875
17 172
26 782
32 681
Intangible Assets
95
75
84
68
112
110
263
3 232
2 960
3 652
Long-Term Investments
3 296
3 891
4 248
3 588
3 194
2 941
2 408
2 572
2 230
8 867
Other Long-Term Assets
1 309
1 317
1 204
1 027
1 408
1 036
1 887
2 263
2 974
1 935
Total Assets
33 464
N/A
34 086
+2%
35 347
+4%
36 385
+3%
38 398
+6%
42 516
+11%
47 775
+12%
73 784
+54%
97 134
+32%
94 937
-2%
Liabilities
Accounts Payable
697
534
783
700
585
586
679
2 932
1 324
1 563
Accrued Liabilities
433
465
558
599
640
743
790
913
1 004
1 088
Short-Term Debt
1 210
1 210
1 210
1 260
2 480
2 780
3 780
12 100
12 100
15 100
Current Portion of Long-Term Debt
891
948
775
464
606
1 028
1 146
768
3 071
2 243
Other Current Liabilities
2 432
1 978
2 741
1 684
2 794
3 547
4 039
12 315
24 555
15 768
Total Current Liabilities
5 664
5 135
6 067
4 707
7 105
8 684
10 434
29 028
42 054
35 762
Long-Term Debt
2 158
1 480
1 208
3 115
2 718
1 923
3 831
5 292
2 994
5 573
Minority Interest
1
1
1
1
185
189
189
174
205
251
Other Liabilities
1 061
1 206
1 009
977
1 047
1 035
931
907
997
1 189
Total Liabilities
8 884
N/A
7 822
-12%
8 285
+6%
8 800
+6%
11 055
+26%
11 831
+7%
15 385
+30%
35 401
+130%
46 250
+31%
42 775
-8%
Equity
Common Stock
9 062
9 062
9 062
9 062
9 061
9 061
9 061
9 061
9 061
9 061
Retained Earnings
4 608
5 943
7 172
8 429
10 813
13 785
15 623
21 421
33 808
35 013
Additional Paid In Capital
10 933
10 950
10 961
10 965
10 947
10 922
10 891
10 941
10 994
10 384
Unrealized Security Profit/Loss
568
733
588
570
462
773
583
691
619
555
Treasury Stock
649
571
782
1 487
4 042
3 937
3 865
3 685
3 600
2 978
Other Equity
58
148
60
47
102
81
97
46
2
127
Total Equity
24 580
N/A
26 264
+7%
27 062
+3%
27 585
+2%
27 343
-1%
30 685
+12%
32 390
+6%
38 383
+19%
50 884
+33%
52 162
+3%
Total Liabilities & Equity
33 464
N/A
34 086
+2%
35 347
+4%
36 385
+3%
38 398
+6%
42 516
+11%
47 775
+12%
73 784
+54%
97 134
+32%
94 937
-2%
Shares Outstanding
Common Shares Outstanding
32
32
127
126
123
123
123
124
124
125

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.